EUVIMEDEUVIMED entdecken
Crossref

Diagnostic Model for Proliferative HCC Using LI‐RADS : Assessing Therapeutic Outcomes in Hepatectomy and TKI‐ICI Combination

Mengtian Lu, Zuyi Yan, Qi Qu, Guodong Zhu, Lei Xu, Maotong Liu, Jifeng Jiang, Chunyan Gu, Ying Chen, Tao Zhang iD, Xueqin Zhang iD

Journal of Magnetic Resonance Imaging · 2025

DOI: 10.1002/jmri.29400 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Magnetic Resonance Imaging, 2025. Verfasst von Mengtian Lu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Nantong University, Nantong, Jiangsu, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Hepatectomy, Magnetic Resonance Imaging. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Science and Technology Project of Nantong City, Nantong Municipal Commission of Health and Family Planning.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Proliferative hepatocellular carcinoma (HCC), aggressive with poor prognosis, and lacks reliable MRI diagnosis.

Purpose

To develop a diagnostic model for proliferative HCC using liver imaging reporting and data system (LI‐RADS) and assess its prognostic value. Study Type Retrospective. Population 241 HCC patients underwent hepatectomy (90 proliferative HCCs: 151 nonproliferative HCCs), divided into the training ( N = 167) and validation ( N = 74) sets. 57 HCC patients received combination therapy with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs). Field Strength/Sequence 3.0 T, T1 ‐ and T2 ‐weighted, diffusion‐weighted, in‐ and out‐phase, T1 high resolution isotropic volume excitation and dynamic gadoxetic acid‐enhanced imaging. Assessment LI‐RADS v2018 and other MRI features (intratumoral artery, substantial hypoenhancing component, hepatobiliary phase peritumoral hypointensity, and irregular tumor margin) were assessed. A diagnostic model for proliferative HCC was established, stratifying patients into high‐ and low‐risk groups. Follow‐up occurred every 3–6 months, and recurrence‐free survival (RFS), progression‐free survival (PFS) and overall survival (OS) in different groups were compared. Statistical Tests Fisher's test or chi‐square test, t ‐test or Mann–Whitney test, logistic regression, Harrell's concordance index (C‐index), Kaplan–Meier curves, and Cox proportional hazards. Significance level: P < 0.05.

Results

The diagnostic model, incorporating corona enhancement, rim arterial phase hyperenhancement, infiltrative appearance, intratumoral artery, and substantial hypoenhancing component, achieved a C‐index of 0.823 (training set) and 0.804 (validation set). Median follow‐up was 32.5 months (interquartile range [IQR], 25.1 months) for postsurgery patients, and 16.8 months (IQR: 13.2 months) for combination‐treated patients. 99 patients experienced recurrence, and 30 demonstrated tumor nonresponse. Differences were significant in RFS and OS rates between high‐risk and low‐risk groups post‐surgery (40.3% vs. 65.8%, 62.3% vs. 90.1%, at 5 years). In combination‐treated patients, PFS rates differed significantly (80.6% vs. 7.7% at 2 years). Data Conclusion The MR‐based model could pre‐treatment identify proliferative HCC and assist in prognosis evaluation. Level of Evidence 4. Technical Efficacy Stage 2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularHepatectomyMagnetic Resonance ImagingHumansMaleFemaleMiddle AgedRetrospective StudiesAgedProtein Kinase InhibitorsTreatment OutcomePrognosisAdultLiverContrast MediaGadolinium DTPA

Stichwörter der Autor:innen

diagnosishepatocellular carcinomaliver imaging reporting and data system

Substanzen

Protein Kinase Inhibitorsgadolinium ethoxybenzyl DTPAContrast MediaGadolinium DTPA

Autor:innen und Institutionen

  • Nantong University, Nantong, Jiangsu, China.
  • Department of Radiology, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People's Hospital, Nantong, Jiangsu, China.
  • Department of Hepatobiliary Surgery, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People's Hospital, Nantong, Jiangsu, China.
  • Department of Pathology, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People's Hospital, Nantong, Jiangsu, China.

ORCID-Profile: Tao Zhang, Xueqin Zhang

Förderung

  • Science and Technology Project of Nantong City
  • Nantong Municipal Commission of Health and Family Planning

Zitieren

APA

Lu, M., Yan, Z., Qu, Q., Zhu, G., Xu, L., Liu, M., Jiang, J., Gu, C., Chen, Y., Zhang, T., & Zhang, X. (2025). Diagnostic Model for Proliferative HCC Using LI‐RADS : Assessing Therapeutic Outcomes in Hepatectomy and TKI‐ICI Combination. Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.29400

Vancouver

Lu M, Yan Z, Qu Q, Zhu G, Xu L, Liu M, et al. Diagnostic Model for Proliferative HCC Using LI‐RADS : Assessing Therapeutic Outcomes in Hepatectomy and TKI‐ICI Combination. Journal of Magnetic Resonance Imaging. 2025. doi:10.1002/jmri.29400

BibTeX
@article{Lu2025,
  author = {Lu, Mengtian and Yan, Zuyi and Qu, Qi and Zhu, Guodong and Xu, Lei and Liu, Maotong and Jiang, Jifeng and Gu, Chunyan and Chen, Ying and Zhang, Tao and Zhang, Xueqin},
  title = {Diagnostic Model for Proliferative HCC Using LI‐RADS : Assessing Therapeutic Outcomes in Hepatectomy and TKI‐ICI Combination},
  journal = {Journal of Magnetic Resonance Imaging},
  year = {2025},
  doi = {10.1002/jmri.29400}
}
Kostenlos starten →